Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

FDA Rx-To-OTC Switch Division Director Leonard-Segal Resigns

This article was originally published in The Tan Sheet

Executive Summary

Andrea Leonard-Segal’s leadership in FDA’s OTC program helped shift the agency toward considering an expanded switch paradigm, and her successor will enter a challenging regulatory environment, stakeholders say.

You may also be interested in...



FDA To Tackle Critical Generics Issue In Switch Paradigm Debate

Commissioner Hamburg says FDA asked for input on a “new paradigm” for nonprescription drug approvals in part because pharmaceutical firms have concerns about whether potential access restrictions imposed on an innovating switch would also apply to generic versions that eventually reach the market.

Warnings Note Disease Treatment Studies Placed Too Close To Supplements For US FDA’s Comfort

Dietary ingredients identified in recent FDA warning letters as linked to disease claims by marketers directing customers to scientific literature include omega-3 fatty acid, ginkgo biloba, glucosamine curcumin and vitamin D.

OTC Decisions November-December: GSK Labels For Nexium Promotion, Voltaren 2-Pack Approved

Approvals by FDA also include revised container and consumer information labeling for J&J's Men’s Rogaine to align with labeling for Women’s Rogaine;  bonus-pack labeling for Bayer AG’s Aleve; and 

Topics

Related Companies

UsernamePublicRestriction

Register

PS051363

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel